APA (7th ed.) Citation

Kołtowski, Ł., Aradi, D., Huczek, Z., Tomaniak, M., Sibbing, D., Filipiak, K. J., . . . Opolski, G. (2016). Study design and rationale for Optimal aNtiplatelet pharmacotherapy guided by bedSIDE genetic or functional TESTing in elective percutaneous coronary intervention patients (ONSIDE TEST): A prospective, open-label, randomised parallel-group multicentre trial (NCT01930773). Kardiologia polska, 74(4), 372. https://doi.org/10.5603/KP.a2015.0172

Chicago Style (17th ed.) Citation

Kołtowski, Łukasz, Daniel Aradi, Zenon Huczek, Mariusz Tomaniak, Dirk Sibbing, Krzysztof J. Filipiak, Janusz Kochman, Paweł Balsam, and Grzegorz Opolski. "Study Design and Rationale for Optimal ANtiplatelet Pharmacotherapy Guided by BedSIDE Genetic or Functional TESTing in Elective Percutaneous Coronary Intervention Patients (ONSIDE TEST): A Prospective, Open-label, Randomised Parallel-group Multicentre Trial (NCT01930773)." Kardiologia Polska 74, no. 4 (2016): 372. https://doi.org/10.5603/KP.a2015.0172.

MLA (9th ed.) Citation

Kołtowski, Łukasz, et al. "Study Design and Rationale for Optimal ANtiplatelet Pharmacotherapy Guided by BedSIDE Genetic or Functional TESTing in Elective Percutaneous Coronary Intervention Patients (ONSIDE TEST): A Prospective, Open-label, Randomised Parallel-group Multicentre Trial (NCT01930773)." Kardiologia Polska, vol. 74, no. 4, 2016, p. 372, https://doi.org/10.5603/KP.a2015.0172.